Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 141,700 shares, a growth of 49.8% from the September 15th total of 94,600 shares. Based on an average trading volume of 445,100 shares, the short-interest ratio is presently 0.3 days. Currently, 15.1% of the shares of the stock are short sold.

Allarity Therapeutics Stock Performance

Shares of ALLR stock opened at $1.39 on Friday. Allarity Therapeutics has a twelve month low of $1.37 and a twelve month high of $666.00. The stock’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.13.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.11) EPS for the quarter. On average, equities analysts anticipate that Allarity Therapeutics will post -78.08 EPS for the current year.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.